Social Media Ideas for Teva Pharmaceuticals

<![CDATA[Pharmaceutical Executive Daily: DualityBio and Teva Strike Major Biopharma Deals]]>

Teva saddles up as stalking horse bidder for bankrupt BioXcel’s neuroscience portfolio

BioXcel Therapeutics has filed for bankruptcy and lined up a deal for Teva Pharmaceutical to acquire its assets for $57.5 million upfront.

Judge OKs $35M Teva Deal In Delayed Generic Inhalers Suit

A Massachusetts federal judge has approved an antitrust settlement that will see Teva Pharmaceuticals pay $35 million to resolve claims that it schemed to delay generic competition...

Teva Seeks to Keep Israel Ties From Philadelphia Jury, Cites Gaza War

Teva Pharmaceuticals has asked a U.S. judge to prevent insurer Humana from telling jurors it is an Israeli company at a major drug price-fixing trial, arguing that strong public vi...

Teva's Turnaround Is Working. Here's the 1 Thing That Could Send It Soaring Another 50%.

The pharmaceutical company has a likely blockbuster drug as the flagship of its pipeline.

Teva claims success in celiac study; BioMarin, Ascendis settle patent dispute

Teva believes the therapy has “pipeline-in-a-product” potential. Elsewhere, a high-stakes trial was paused and GSK advanced a competitor to Moderna’s flu shot.

7th Circ. Revives Teva Suit Over Eli Lilly Generic Drug Block

The Seventh Circuit on Monday revived a breach-of-contract lawsuit against Eli Lilly, ruling that an earlier legal settlement under which Eli Lilly agreed not to block the approval...

BioXcel files for Chapter 11, will sell assets to Teva

<![CDATA[M&A Roundup: DualityBio & Genentech Enter Partnership to Develop Next Generation ADC’s, Teva Bids to...

Dear Teva Pharmaceutical Stock Fans, Mark Your Calendars for September 14

Pharma giant Teva seeks to hide Israel ties from U.S. jury in price-fixing trial

The company argued that strong public views over the Gaza war could prejudice proceedings and affect its ability to receive a fair hearing. The filing underscored how tensions over...

Practical Guidance for Pharmaceutical Method-of-Use Patent Claims After Teva v. Eli Lilly and In re Xencor

Teva autoimmune antibody notches ph. 2 win in celiac disease

Teva Pharmaceutical's dreams of a first-in-class autoimmune blockbuster are being kept alive after the Israeli outfit’s anti-interleukin-15 antibody scored a midstage win in celiac...

Teva Drug Rises to the Gluten Challenge, Stopping Intestinal Damage in Celiac Disease Trial

In a mid-stage study, Teva’s drug prevented intestinal damage in celiac disease patients who underwent a gluten challenge — eating food with gluten to see if it prompts an immune r...

<![CDATA[Sandoz Agrees to $450 Million Settlement With 43 US States Over Generic Drug Antitrust Claims]]>

<![CDATA[Roundup: Alteogen Enters Option & License Agreement with Novartis, NewBiologix & Synastra Form BioTe...

Will Israel's Teva's new celiac medication be the best thing since sliced bread?

Israeli giant Teva announced positive results in an ongoing study of a new antibody, that protects sufferers of the disease from harm triggered by gluten

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Subcutaneous Formulation of Leqembi Iqlik]]>

Tepezza Expansion feedback

Tepezza Expansion feedback Anonymous (not verified) Wed, 07/22/2026 - 15:21 field_thread_url https://cafepharma.com/boards/threads/tepezza-expansion-feedba...

<![CDATA[Pharmaceutical Executive Daily: FDA Issues CRL to Elevar Therapeutics]]>

<![CDATA[Pharmaceutical Executive Daily: Nine Companies Strike Deals for MFN Pricing]]>

Pharmaceutical Method-of-Use Claims After Teva v. Eli Lilly and In re Xencor: Written Description, Enablement, and the K...

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Simtriyo]]>

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Viatris's Gwyn Lo]]>